Channel Therapeutics Corporation, formerly Chromocell Therapeutics Corporation, is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel, NaV1.7, which has been genetically validated as a pain receptor in human physiology. It operates three programs developing pain treatment therapeutics: Neuropathic Pain, Eye Pain, and Depot. It is engaged in developing, CC8464, to address certain types of neuropathic pain. The chemical characteristics of CC8464 restrict its entry into the CNS and limit its effect to the NaV1.7 channels in the peripheral nervous system. Based on a novel formulation of CC8464, its Eye Pain program, titled CT2000, is for the potential treatment of both acute and chronic eye pain. Based on several novel formulations of CC8464, its program, titled CT3000, is for the potential treatment of postoperative pain with the use of nerve blocks.